CoreLab LOCATIONS | 1.877.632.9432 | Client Portal
 

Resources


CoreLab Partners is pleased to provide relevant resources designed to aid your search for information. Here you will find published papers, a glossary of pharmaceutical development terms and links to relevant websites.

Please check this space often as we continue to improve and expand our resource library.

If you have any questions or ideas, please contact us.
 

Published Papers

Title

  Author / Date

Publication

A potential new approach to assessing PFS in solid tumor studies
 
Kristin Borradaile, Kevin Duffy, Michael O'Neal
 
ICT May 2013
Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium

Philip Sager, MD, FACC, Jeffrey Heilbraun, MS, J. Rick Turner, PhD, et al. Am Heart Journal 2013; 165:477-88
A Paradigm in Evolution
 
O'Neal, Strafaci, Scarimbolo and Van Heertum European Pharmaceutical Contractor (EPC) March 2013
 
Sustained Blood Pressure-Lowering Affect of Aliskiren Compared with Telmisartan After a Single Missed Dose
 
 Rainer Dusing, Md et al Journal of Clinical Hypertension 2012
Sustained Decrease in Blood Pressure Following Missed Doses of Aliskiren or Telmisarten: the Assertive Double-Blind Randomized Study 
 
 Rainer Dusing, Patrick Brunel, et al Journal of Hypertension 2012
Blood pressure evaluation and drug induced blood pressure changes
 
 Jeff Heilbruan, Ms CBI Cardiac Safety Summit, Jan2012
No Limits_Evolution of DXA
 
A. Spano Lander, R. Rupich ICT Feb 2011
Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thorasic phantom imaging
 
N. Petrick, H. Grace Kim, D. Clunie, et al Proc of SPIE, vol 7963, 7963DD
Discordance Between BICR Readers  K. Borradaile, R. Ford, et al  Applied Clinical Trials, Nov 2010
Brain Magnetic Resonance Imaging in Adults with Asthma  J. Parker, L.J. Wolansky, et al Contemprorary Clinical Trials 32, Oct 2010

Analysis of the Cause of Discordance Between Two Radiologists in the Assessment of Radiographic Response and Progression for Subjects Enrolled in Breast Cancer Clinical Trials Employing Blinded Independent Central Review

 Kristin Borradaile MS, et al

 

ASCO Poster 2010

       

Analysis of the Rate of Non-target Disease Progression in Patients with Stable or Responding Target Disease by the Response Evaluation Criteria in Solid Tumors (RECIST)

 Kristin Borradaile, et al

 

ASCO 2009

       

The Impact of the Inclusion of Clinical Data Review on Overall Radiographic Response and Progression in Oncology Clinical Trials as Assessed by Blinded Independent Central Review

 Nicolette Wangler, et al

 

ASCO 2009

       

Computer-Assisted Photographic Evaluation in Rheumatology (CAPER gout tophi)

 A.N. Maroli et al.

 

ACR Presented Poster

       

Recommendations for the assessment of progression in randomised cancer treatment trials

  J.E. Dancy , et al.

 

EJC 45 (2009)

       

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

  E.A. Eisenhaur, et al.

 

EJC 45 (2009)

       

Lessons learned from independent central review

  Dr. Robert Ford, et al.

 

ECJ 45 (Jan 2009)

       

Individual patient data analysis to assess modifications to the RECIST criteria

  Jan Bogaerts , et al.

 

EJC 45 (2009)

       

Report of Task Force II: Best Practices in the Use of Medical Imaging Techniques in Clinical Trials

  Dr. Robert Ford, et al.

 

Task Force II

       

Analysis of the Rate of Missing Data, the Rate of Discordance between Readers, and the Rate of Site versus Central Discordance in Clinical Studies of Recently Approved Breast Cancer Agents that Have Used Blinded Independent Central Review

  Kristin Borradaile

 

SABCS presented poster

       

Applying PMBOK Principles to Clinical Submission

  Lance Wolf

 

PMI Pharmaceutical

       

A Retrospective Exploratory Study of the Variability of Radiologists Measurements in a Selected Subgroup of Subjects Enrolled in a Clinical Trial

  Dr. Robert Ford, et al.

 

 

       

Inter-observer Variability in Radiographic Assessment of Response in Chemotherapy Trials for Pancreatic Cancer

  Brian C. Baumann, AB,   et al.
  June 2007

ASCO presented poster

       

Evaluation of Number of Target Lesions to Analyze in
Time to Progression by RECIST

  Mithat Gönen, et al.

 

ASCO presented poster

     
DICOM Structured Reporting and Cancer Clinical Trials Results   David A. Clunie
  May 2007
Cancer Informatics 
     
DICOM structured reporting: an object model as an implementation boundary (SPIE MI 2001)   David A. Clunie
  2001
SPIE MI

 


Links

Glossary of terms

Organizations

Association of Clinical Research Organizations
www.acrohealth.org

Association of Clinical Research professionals
www.acrpnet.org

American Society of Clinical Oncology (ASCO)
www.asco.org

American Society of Hematology (ASH)
www.hematology.org

Biotechnology Industry Organization
www.bio.org

CDISC – clinical Data Interchange Standards Consortium
www.cdisc.org

CISCRP – Center for Information & Study on Clinical Research Participation
www.ciscrp.org

Drug Information Association
www.diahome.org

Regulatory Affairs Professionals Society
www.raps.org

Society for Clinical Data Management
www.scdm.org

Society of Clinical Research Associates
www.socra.org


FDA Sites

FDA Home page
www.fda.gov

FDA – European Union
www.fda.gov/oia/EC_EMEA.htm

The Center for Biologics Evaluation and Research (CBER)
http://www.fda.gov/cber/guidelines.htm

The Center for Drug Evaluation and Research (CDER)
http://www.fda.gov/cder

The Office of Regulatory Affairs (ORA)
http://www.fda.gov/ora


Government Sites

European Medicines Agency
http://www.emea.europa.eu

National Institutes of Health
http://www.nih.gov

Agency for Healthcare Research and Quality (AHRQ)
http://www.ahrq.gov